CLINICAL_TRIALS ClinicalTrials.gov record update

Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04491370
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:54.677658+00:00
Published At: 2026-04-15T00:00:00+00:00
Record Updated At: 2026-04-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["B-cell Lymphoma", "Burkitt Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Transformed Non-Hodgkin Lymphoma", "Richter Syndrome", "Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-15"
protocolSection.identificationModule.nctId: "NCT04491370"
protocolSection.identificationModule.officialTitle: "Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.